- Immunocompromised with clinically compatible illness.
- Diagnosis of proven or probable or possible Invasive Aspergillosis (based on a
modified version of the revised EORTC/MSG consensus definitions).
- Diagnosis of infection due to Scedosporium or Fusarium species.
- Male and female from 2 to 17 years of age.
- Females with childbearing potential must have negative pregnancy test and be using
- Allergy or hypersensitivity to the azole drugs.
- Female subjects who are pregnant or lactating.
- Patients who received more than four days of antifungal drugs to treat the current
episode of invasive aspergillosis or rare mold infection.
- Received within 24 hours prior to enrollment drugs that may cause QT interval
- Significant liver, kidney or heart dysfunction.
- Not expected to survive for at least 5 days.